Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
12,543
Total Claims
$2.4M
Drug Cost
636
Beneficiaries
$3,841
Cost/Patient
Risk Score Breakdown 13/100
Score components are additive. Read full methodology
Peer Comparison vs. 18,720 Cardiology providers
+152%
Cost per patient vs peers
$3,841 vs $1,524 avg
+54%
Brand preference vs peers
21.0% vs 13.7% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.1%
Opioid Rate
13
Opioid Claims
$120
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,622 claims · $2.2M
Generic: 9,856 claims · $258K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 421 | $352K |
| Rivaroxaban | 228 | $190K |
| Sacubitril/Valsartan | 164 | $161K |
| Semaglutide | 109 | $149K |
| Dulaglutide | 104 | $143K |
| Empagliflozin | 159 | $135K |
| Evolocumab | 143 | $100K |
| Dapagliflozin Propanediol | 91 | $93K |
| Fluticasone/Umeclidin/Vilanter | 87 | $68K |
| Alirocumab | 93 | $63K |
| Finerenone | 58 | $49K |
| Exenatide Microspheres | 27 | $32K |
| Ivabradine Hcl | 36 | $28K |
| Insulin Degludec | 42 | $23K |
| Empagliflozin/Metformin Hcl | 14 | $23K |
Prescribing Profile
Patient Profile
76
Avg Age
47%
Female
1.28
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About